GlassScriptPhysician profile
Avikshitha Sudhakara
NPI 1679937189
$9,365.74
in general payments reported to CMS, 2019-2025
54 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $153 · 2021: $2,306 · 2022: $2,254 · 2023: $1,301 · 2024: $1,840 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,652.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,386.24 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,169.32 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $928.76 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $711.37 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $659.73 | 2021-2022 | |
| Abbvie INC. | $476.25 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $327.90 | 2020-2024 | Xifaxan |
| Antares Pharma, INC. | $300.93 | 2022-2025 | Xyosted |
| Spineology INC. | $258.50 | 2025 | Optimesh Expandable Interbody Fusion System |
| Amgen INC. | $230.94 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $219.11 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $205.35 | 2022-2024 | Quviviq |
| Pfizer INC. | $179.80 | 2021-2025 | |
| Alkermes, INC. | $150.94 | 2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $148.09 | 2020-2023 | Ajovy |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avikshitha Sudhakara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.